Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Tango Clinical Trials
- Phone Number: (857) 320-4899
- Email: clinicaltrials@tangotx.com
Study Locations
-
-
-
Bordeaux, France, 33000
- Institut Bergonie
-
Lyon, France, 69373
- Centre Léon Bérard
-
Saint-Herblain, France, 44805
- EDOG Institut de Cancerologie de l'Ouest
-
Toulouse, France, 31059
- Institut Oncopole Claudius Regaud
-
Villejuif, France, 94805
- Institute Gustav Roussy
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- University of California Los Angeles
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Sarah Cannon Research Institute at HealthONE
-
Grand Junction, Colorado, United States, 81505
- Grand Valley Oncology
-
-
Florida
-
Lake Mary, Florida, United States, 32746
- Florida Cancer Specialists & Research Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
Urbana, Illinois, United States, 61801
- Carle Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, United States, 63110
- Washington University
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
New York, New York, United States, 10022
- Memorial Sloan Kettering Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Tennessee Oncology
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas MD Anderson Cancer Center
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- NEXT Oncology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: ≥18 years-of-age at the time of signature of the main study ICF
- Performance status: ECOG Performance Score of 0 to 1 or Karnofsky performance status score ≥70.
- Confirmed histologic or cytologic diagnosis of a locally advanced, metastatic, and/or unresectable solid tumor or for GBM, have R/R disease.
- Prior standard therapy, as available
- Documented bi-allelic (homozygous) deletion of MTAP in a tumor detected by next- generation sequencing or absence of MTAP protein in a tumor detected by IHC.
- Adequate organ function/reserve per local labs
- Adequate liver function per local labs
- Adequate renal function per local labs
- Negative serum pregnancy test result at screening
- Written informed consent must be obtained according to local guidelines
Exclusion Criteria:
- Known allergies, hypersensitivity, or intolerance to TNG908 or its excipients
- Uncontrolled intercurrent illness that will limit compliance with the study requirements
- Active infection requiring systemic therapy
- Currently participating in or has planned participation in a study of another investigational agent or device
- Impairment of GI function or disease that may significantly alter the absorption of oral TNG908
- Active prior or concurrent malignancy.
- Central nervous system metastases associated with progressive neurological symptoms
- Current active liver disease from any cause
Known to be HIV positive, unless all of the following criteria are met:
- CD4+ count ≥300/μL
- Undetectable viral load
- Receiving highly active antiretroviral therapy
- Clinically relevant cardiovascular disease
- A female patient who is pregnant or lactating
- Patient is unwilling or unable to comply with the scheduled visits, drug administration plan, laboratory tests, biopsy, or other study procedures and study restrictions
- Patient has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, may affect the safety of the patient or impair the assessment of study results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose Escalation
Participants with MTAP-deleted solid tumors will receive escalating doses of TNG908 to estimate the MTD
|
TNG908, a selective PRMT5 inhibitor, will be administered orally
|
|
Experimental: Dose Expansion in NSCLC
Participants with MTAP-deleted NSCLC (squamous and non squamous) will receive TNG908 at the identified RP2D
|
TNG908, a selective PRMT5 inhibitor, will be administered orally
|
|
Experimental: Dose Expansion in Mesothelioma
Participants with MTAP-deleted mesothelioma will receive TNG908 at the identified RP2D
|
TNG908, a selective PRMT5 inhibitor, will be administered orally
|
|
Experimental: Dose Expansion in Glioblastoma
Participants with MTAP-deleted relapsed/refractory glioblastoma will receive TNG908 at the identified RP2D
|
TNG908, a selective PRMT5 inhibitor, will be administered orally
|
|
Experimental: Dose Expansion in Pancreatic Ductal Adenocarcinoma
Participants with MTAP-deleted pancreatic ductal adenocarcinoma will receive TNG908 at the identified RP2D
|
TNG908, a selective PRMT5 inhibitor, will be administered orally
|
|
Experimental: Dose Expansion in Sarcoma
Participants with MTAP-deleted sarcoma (soft tissue and bone) will receive TNG908 at the identified RP2D
|
TNG908, a selective PRMT5 inhibitor, will be administered orally
|
|
Experimental: Dose Expansion in solid tumors
Participants with other MTAP-deleted solid tumors will receive TNG908 at the identified RP2D
|
TNG908, a selective PRMT5 inhibitor, will be administered orally
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase 1:
Time Frame: 28 days
|
To determine the MTD and dosing schedule of TNG908
|
28 days
|
|
Phase 2:
Time Frame: 16 weeks
|
To assess anti-neoplastic activity of TNG908 in patients with MTAP-deleted advanced solid tumors by RECIST or mRECIST v1.1 or modified RANO criteria
|
16 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phase 1 and 2:
Time Frame: 28 days
|
To describe the safety and tolerability profile of TNG908 by frequency and severity of AEs
|
28 days
|
|
Phase 1 and 2:
Time Frame: 16 days
|
Area under the plasma concentration versus time curve (AUC)
|
16 days
|
|
Phase 1 and 2:
Time Frame: 16 days
|
Time to achieve maximal plasma concentration (Tmax)
|
16 days
|
|
Phase 1 and 2:
Time Frame: 16 days
|
Maximum observed plasma concentration (Cmax)
|
16 days
|
|
Phase 1 and 2:
Time Frame: 16 days
|
Terminal elimination half-life (t1/2)
|
16 days
|
|
Phase 1 and 2:
Time Frame: 16 days
|
Apparent total plasma clearance when dosed orally (CL/F)
|
16 days
|
|
Phase 1 and 2:
Time Frame: 16 days
|
Apparent volume of distribution when dosed orally (Vz/F)
|
16 days
|
|
Phase 1 and 2:
Time Frame: 28 days
|
SDMA levels in tumor tissue will be assessed pre-treatment and post treatment with TNG908
|
28 days
|
|
Phase 1:
Time Frame: 16 weeks
|
To assess preliminary evidence of anti-neoplastic activity of TNG908 in patients with MTAP-deleted advanced solid tumors by RECIST or mRECIST v1.1or modified RANO criteria
|
16 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Maxim Pimkin, MD, PhD, Tango Therapeutics, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Adenoma
- Neoplasms, Mesothelial
- Carcinoma
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Nervous System Neoplasms
- Nerve Sheath Neoplasms
- Peripheral Nervous System Neoplasms
- Neoplasms, Connective and Soft Tissue
- Neoplasms, Connective Tissue
- Neurofibroma
- Fibrosarcoma
- Neoplasms, Fibrous Tissue
- Mesothelioma
- Glioblastoma
- Cholangiocarcinoma
- Sarcoma
- Neurofibrosarcoma
Other Study ID Numbers
Other Study ID Numbers
- TNG908-C101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.